Mycoplasma pneumonia is a lung infection caused by the bacterium Mycoplasma pneumoniae, one of the most common causes of community-acquired pneumonia, particularly in school-age children and young adults. It earned the old nickname “walking pneumonia” because people often stay on their feet through it, feeling unwell but not bedridden. The infection is more complex than that reputation suggests, though, with a bacterium that defies some basic assumptions about how bacteria work and a disease course that can occasionally veer into unexpected territory.
A Bacterium Without a Cell Wall
M. pneumoniae is one of the smallest self-replicating organisms known, and its most distinctive feature is what it lacks: a cell wall. Most bacteria are wrapped in a rigid cell wall, which is the target of some of the most widely prescribed antibiotics, including penicillin and other beta-lactams. Because M. pneumoniae has no cell wall, those drugs are useless against it.1PubMed Central. Mycoplasma pneumoniae pneumonia in children This is one reason mycoplasma infections get missed or mistreated early on. A doctor prescribing amoxicillin for what looks like a typical chest infection will see no improvement if M. pneumoniae is the culprit.
The missing cell wall also means the organism cannot be visualized with Gram staining, a standard lab technique used to classify bacteria.2PubMed Central. Mycoplasma pneumoniae pneumonia in children It slips through one of the first diagnostic steps a microbiology lab would normally use.
Instead of brute-forcing its way into lung tissue the way some aggressive bacteria do, M. pneumoniae uses a specialized structure called a terminal organelle to latch onto the cells lining the airways. A protein called P1 acts as the primary adhesin, binding to sugar molecules on respiratory epithelial cells. Strains that lose P1 lose their ability to attach and become non-pathogenic entirely.3PubMed Central. Advances in adhesion-related pathogenesis in Mycoplasma pneumoniae infection Once attached, the bacterium nestles between cells, avoiding the sweeping action of cilia and the reach of immune cells. It essentially hides in a blind spot.
How It Causes Damage
Much of the harm from a mycoplasma infection comes not from direct tissue destruction but from the immune response the bacterium provokes. M. pneumoniae produces a toxin known as CARDS toxin (short for community-acquired respiratory distress syndrome toxin), which triggers a cascade of inflammation in the lungs. In animal studies, exposure to this toxin alone, without live bacteria, was enough to produce histological changes in the lungs that closely resembled what the full infection causes.4American Journal of Respiratory Cell and Molecular Biology. The Immunopathologic Effects of Mycoplasma pneumoniae and Community-acquired Respiratory Distress Syndrome Toxin. A Primate Model
CARDS toxin ramps up production of inflammatory signaling molecules and triggers a strong eosinophilic response, a type of immune reaction more commonly associated with allergies and asthma than with bacterial infections. In mice, a single dose of the toxin induced a dramatic increase in allergy-related immune signals and led to mucus overproduction and airway hyperreactivity.5PubMed Central. Mycoplasma pneumoniae CARDS Toxin Induces Pulmonary Eosinophilic and Lymphocytic Inflammation This overlap between infection and allergic-type inflammation helps explain why mycoplasma pneumonia can sometimes trigger asthma flare-ups or new-onset wheezing, even in people without a prior history of asthma.
How It Spreads and Who Gets It
The bacterium spreads through respiratory droplets, the same route as colds and flu. What makes it unusual is the long incubation period. From exposure to symptoms, the typical wait is about two to four weeks, with one family study estimating a median of 23 days.6JAMA. Epidemiology of Mycoplasma pneumoniae Infection in Families That slow burn means an infected person can be contagious for weeks before anyone realizes they are sick, which is partly why outbreaks in schools, dormitories, and military barracks tend to smolder for a long time before they are recognized.7PubMed Central. Applying Network Theory to Epidemics: Control Measures for Mycoplasma pneumoniae Outbreaks
Household transmission is common. In one classic study of 36 families with a confirmed index case, the infection spread to other family members in roughly two thirds of households. Children were especially susceptible, with about 84% of children in affected families becoming infected compared with 41% of adults.8JAMA. Epidemiology of Mycoplasma pneumoniae Infection in Families Not all of those infections produced pneumonia; some family members had only sore throats or no symptoms at all.
After COVID-19 pandemic restrictions lifted, M. pneumoniae staged a dramatic global comeback. Cases had dropped to near-zero during lockdowns, likely because social distancing and masking disrupted its transmission cycle. By late 2023, simultaneous epidemic surges were detected across countries in all four United Nations world regions.9The Lancet Microbe. Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study Researchers linked the timing of this rebound partly to the bacterium’s long incubation period, which delayed the resurgence even after population mixing returned to normal.
Symptoms and What to Expect
Mycoplasma pneumonia tends to come on gradually. The stereotypical pattern is a persistent dry, hacking cough that may linger for weeks, accompanied by low-grade fever, fatigue, and sometimes a headache or sore throat. In children, fever and dry cough are hallmark features, distinguishing it somewhat from pneumonia caused by Streptococcus pneumoniae, which is more likely to cause wheezing and higher white blood cell counts in younger patients.10PubMed Central. Clinical differences between Mycoplasma pneumoniae pneumonia and Streptococcus pneumoniae pneumonia: a case control study That study also found that age itself was a useful distinguishing factor: children over about four years old with community-acquired pneumonia were more likely to have mycoplasma than those under four.
Adults and children can present quite differently. A comparison of over 200 mycoplasma pneumonia patients found significant differences in the inflammatory response, clotting markers, and patterns of organ involvement between adults and children.11PubMed. A comparison of diagnostic and therapeutic approaches for Mycoplasma pneumoniae pneumonia in children and adults, during the post-COVID-19 pandemic era In adults, elevated C-reactive protein was strongly associated with more severe disease, while in children, liver enzyme levels and potassium levels were additional markers of severity.
On imaging, mycoplasma pneumonia often looks different from the dense white-outs typical of bacterial lobar pneumonia. Chest CT scans commonly show thickened bronchial walls, small nodules clustered around the smallest airways, and patchy ground-glass opacities rather than heavy consolidation.12PubMed Central. Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing Bilateral bronchial wall thickening or centrilobular nodules seen on CT were actually found exclusively in mycoplasma patients and not in those with S. pneumoniae infection, making those findings useful diagnostic clues. In children, hazy or ground-glass patterns are frequent, but the dense homogeneous consolidation typical of other bacterial pneumonias is uncommon.13PubMed. Spectrum of clinical and radiographic findings in pediatric mycoplasma pneumonia
Why Diagnosis Is Tricky
Diagnosing mycoplasma pneumonia with certainty is harder than it should be. The organism does not grow on standard culture media, Gram stains miss it, and the available tests each have drawbacks. Blood tests for antibodies (serology) take time because the body may not produce detectable antibodies until a week or more into the illness. PCR testing, which detects the bacterium’s DNA directly from a throat or nasal swab, is faster and highly specific, but its sensitivity varies. A meta-analysis of 14 studies found that while PCR’s specificity was excellent (around 96%), its sensitivity ranged widely and averaged about 62%, meaning it misses a substantial number of true infections.14PubMed Central. PCR versus serology for diagnosing Mycoplasma pneumoniae infection: A systematic review & meta-analysis
A complicating wrinkle is that M. pneumoniae can live in the throats of perfectly healthy people. One study of children found the bacterium’s DNA in roughly 21% of asymptomatic kids and 16% of those with respiratory symptoms, and neither serology, PCR, nor culture could reliably tell the difference between harmless carriage and actual infection.15PLoS Medicine. Carriage of Mycoplasma pneumoniae in the Upper Respiratory Tract of Symptomatic and Asymptomatic Children: An Observational Study This means a positive test does not necessarily prove that M. pneumoniae is causing the current illness, which makes treatment decisions less straightforward than they appear.16PubMed. Mycoplasma pneumoniae infections–does treatment help?
Newer point-of-care molecular tests are showing promise for faster, more reliable bedside diagnosis. One evaluation of a molecular rapid test showed sensitivity above 97% and specificity near 99% for detecting M. pneumoniae.17PubMed Central. An Evaluation of a Molecular Point-of-Care Testing System Designed for Early Diagnosis of Mycoplasma pneumoniae and Respiratory Syncytial Virus Infections If these tools become widely available, they could substantially reduce the diagnostic guesswork. But the carriage problem would remain: a positive test still would not tell you whether the bacterium found in the nose is the one causing the pneumonia.
Treatment and the Growing Resistance Problem
The standard first-line treatment for mycoplasma pneumonia is a macrolide antibiotic, most commonly azithromycin. For uncomplicated cases, a short course of azithromycin clears the infection effectively, shortening fever duration and speeding recovery compared to supportive care alone.18PubMed Central. Clinical Efficacy of Azithromycin in the Treatment of Pediatric Mycoplasma pneumoniae Pneumonia and Its Impact on Platelet Count and D-Dimer Levels
The catch is that macrolide resistance has been climbing, and it varies enormously by geography. In the United States, a national surveillance program from 2015 to 2018 found macrolide-resistant strains in about 7.5% of specimens overall, though the rate was nearly 18% in the southern and eastern states versus only about 2% in the west.19Journal of Clinical Microbiology. Macrolide-resistant mycoplasma pneumoniae in the United States as determined from a national surveillance program In parts of East Asia, the picture is far worse. A study of children in Urumqi, China, during the 2023–2024 season found macrolide resistance in over 99% of tested samples.20PubMed. Molecular characteristics of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Urumqi, Xinjiang, China in autumn, winter, and spring 2023-2024 A 2023 outbreak in northern Vietnam found resistance mutations in nearly half of isolates tested.21Emerging Infectious Diseases. Novel Variant and Known Mutation in 23S rRNA Gene of Mycoplasma pneumoniae, Northern Vietnam, 2023 The dominant mutation behind this resistance, a change called A2063G in the 23S ribosomal RNA gene, shows up consistently across studies worldwide.
When macrolides fail, the backup options are limited. Tetracyclines (such as doxycycline or minocycline) and fluoroquinolones remain effective, and minocycline in particular has been shown to shorten fever in children with macrolide-resistant infections more effectively than other alternatives.22PLoS ONE. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients However, tetracyclines can stain developing teeth, which historically limited their use in young children, and fluoroquinolones carry their own concerns about tendon and cartilage effects in growing bodies. In severe or refractory cases, corticosteroids are sometimes added to antibiotics to tamp down the inflammatory component of the disease.23PubMed Central. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children
When It Spreads Beyond the Lungs
One of the more surprising aspects of mycoplasma infection is its ability to cause problems far from the respiratory tract. Extrapulmonary complications are well documented and can affect the skin, the eyes, the nervous system, and other organs.
The most recognized skin manifestation is called MIRM (Mycoplasma pneumoniae-induced rash and mucositis). It typically strikes children and young adults and causes painful sores on the mucous membranes of the mouth, eyes, and genitals, sometimes with a rash on the skin. The mucosal involvement can be severe enough to mimic Stevens-Johnson syndrome, a more dangerous drug-reaction condition, though the prognosis for MIRM is generally better.24PubMed Central. Mycoplasma pneumoniae-Induced Rash and Mucositis: Clinicopathologic Characterization of 11 Cases The skin changes are thought to be driven by immune complex deposition rather than by direct bacterial invasion.25PubMed Central. Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Systematic Review of the Literature Eye involvement in MIRM can include conjunctivitis and corneal inflammation; while the long-term visual outcome is usually good, some patients have needed interventions such as amniotic membrane transplantation to protect the corneal surface.26PubMed. Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Longitudinal Perspective and Proposed Management Criteria
Neurological complications are rarer but potentially serious. The list includes encephalitis, Guillain-Barré syndrome, transverse myelitis, cranial nerve palsies, and acute demyelinating encephalomyelitis, all of which appear to be immune-mediated rather than caused by the bacterium directly invading the brain.27PubMed Central. Mycoplasma Pneumoniae Infection with Neurologic Complications These complications sometimes arise days to weeks after the respiratory illness has resolved, which can make the connection easy to miss if nobody considers mycoplasma as a trigger.
Co-infections and Why They Matter
In real-world clinical settings, M. pneumoniae does not always act alone. Children hospitalized with mycoplasma pneumonia who also carried a respiratory virus at the same time had longer hospital stays, more prolonged fevers after admission, and a higher rate of extrapulmonary complications compared to those with mycoplasma alone.28PubMed Central. Significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia This is worth knowing for parents whose children test positive for both mycoplasma and, say, RSV or influenza. Co-infection is not just two mild illnesses stacked together; it can push the overall severity beyond what either pathogen would cause on its own.
Long-Term Lung Effects and the Asthma Connection
Most people recover from mycoplasma pneumonia without lasting problems, but research suggests the infection can leave a mark on the airways that lasts years. Studies have found signs of small-airway obstruction one to two years after the infection, even in people who felt fully recovered. In one study, children examined up to 9.5 years after a mycoplasma respiratory infection showed measurable impairment in airflow through the small airways, despite having no ongoing symptoms and no underlying lung disease.29PubMed Central. Mycoplasma pneumoniae and its role in asthma The macrolide antibiotics used to treat mycoplasma are bacteriostatic, meaning they stop the bacterium from growing rather than killing it outright, which may allow the organism to persist at low levels and sustain chronic low-grade inflammation.
Animal models reinforce this picture. Mice inoculated with M. pneumoniae developed elevated airway hyperreactivity that was still measurable more than 500 days after the initial infection, alongside chronic histological inflammation in the lungs.30PubMed Central. Mycoplasma pneumoniae induces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease The CARDS toxin research described earlier fits neatly into this picture: a toxin that induces an allergic-type immune response in the lungs could plausibly contribute to the development or worsening of asthma, and that connection has been a focus of ongoing investigation.
Vaccine Prospects
There is currently no approved vaccine against M. pneumoniae, despite efforts that date back to the 1960s.31PubMed. Oral vaccination with live Mycoplasma pneumoniae elicits a respiratory protective immunity in a murine model Early inactivated vaccines ran into a frustrating problem: rather than protecting against infection, they sometimes enhanced disease upon subsequent natural exposure, presumably by priming the immune system in a way that worsened the inflammatory response. This phenomenon has made researchers cautious, and progress has been slow.
Several newer approaches are under investigation, including live attenuated strains, recombinant protein vaccines targeting the P1 adhesin, and even oral vaccination strategies. Some of these have shown protective effects in mouse models, but the jump from mice to a safe, effective human vaccine remains a formidable challenge. Given the growing problem of macrolide resistance and the post-pandemic surges, a working vaccine would be a significant advance. For now, though, the field is still in preclinical and early-stage research, and a commercially available vaccine is likely years away at best.